Libroxar

Buprenorphine/Naloxone, the active ingredient in Libroxar, is a partial opioid agonist / opioid antagonist combination presented as a sublingual tablet for sublingual use. It is indicated for the management of opioid dependence and opioid use disorder, helping to reduce withdrawal symptoms and curb misuse in adult patients.

GNH USA supplies Libroxar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets.

Libroxar (buprenorphine/naloxone) is used in the opioid dependence treatment pathway to manage opioid use disorder.

- Opioid dependence: reduces withdrawal symptoms and cravings, supporting stable maintenance. - Opioid use disorder: facilitates relapse prevention and transition to opioid‑free status. - Opioid addiction: aids in long‑term recovery by providing controlled opioid receptor activity.

Common Side Effects: - Nausea - Constipation - Headache - Sweating - Dry mouth - Dizziness

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Allergic reactions (including anaphylaxis) - Liver enzyme elevation - Seizures - QT interval prolongation

Libroxar requires careful clinical monitoring due to its opioid activity and formulation. - Assess patient history: evaluate prior opioid use, dependence severity, and comorbid conditions. - Monitor for respiratory depression: especially during induction and dose adjustments. - Avoid use in severe hepatic impairment: consider alternative therapy or dose modification. - Caution with concomitant CNS depressants: increased risk of sedation and respiratory effects. - Pregnancy and breastfeeding: weigh benefits against potential risks; consult specialist. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Libroxar may interact with several drug classes that affect opioid pathways or central nervous system function.

Major Interactions (Avoid): - Full opioid agonists (e.g., morphine, heroin): risk of precipitated withdrawal. - Benzodiazepines: additive CNS depression and respiratory risk. - Alcohol: increased sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise buprenorphine levels. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Antidepressants (e.g., SSRIs, SNRIs): monitor for serotonin syndrome.